Clinical Trial Update: Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 perioperative study of panitumumab with EOX chemotherapy in gastroesophageal adenocarcinoma; the trial was terminated with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• Epirubicin (epirubicin)
• OXALIPLATIN (Oxaliplatin)
• Panitumumab (panitumumab)
• Xeloda (capecitabine)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Esophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-07-04